Corporate ActionMay 22, 2026, 04:53 PM
Nanobiotix Underwriters Fully Exercise Option; $100M Gross Proceeds
AI Summary
Nanobiotix announced that the underwriters of its global offering fully exercised their over-allotment option to purchase 33,805 additional American Depositary Shares (ADSs). This brings the total gross proceeds from the offering to approximately $100 million (€86.1 million). The company intends to use the net proceeds to advance its Nanoprimer and other platforms (50-60%), for general corporate purposes (30-40%), and to support the development of JNJ-1900 (NBTXR3) (<10%). The company believes these proceeds, combined with existing cash, will fund operations into 2029.
Key Highlights
- Underwriters fully exercised over-allotment option for 33,805 additional ADSs.
- Global Offering gross proceeds reached approximately $100 million (€86.1 million).
- Total shares issued: 2,218,467 Ordinary Shares and 345,099 pre-funded warrants.
- Offering price: $38.98 per Additional ADS, corresponding to €33.60 per Ordinary Share.
- Proceeds allocation: <10% for JNJ-1900, 50-60% for Nanoprimer, 30-40% for general corporate purposes.
- Company expects cash and equivalents to fund operations into 2029.
Price Impact
More from NBTX